A clinicopathological analysis of adrenal tumors in patients with history of extra-adrenal cancers

Lei Tan, Yunlin Ye, Kanghua Xiao, Xuelian Xu, Haitao Liang, Fufu Zheng and Zike Qin

Abstract

Background: Adrenal tumors in patients with previous/synchronous extra-adrenal malignancy are diverse and are a dilemma in clinical practice. This study investigated the differentiation of adrenal malignant and benign tumors in these patients.

Methods: Data from patients with a pathological diagnosis of adrenal tumors were retrospectively retrieved from April 1991 to November 2015. Patients without extra-adrenal malignancy were excluded. Clinical and imaging characteristics, including sex, age, tumor size, tumor location, isolated lesion, time interval between the diagnosis of the two tumors and retrieved imaging diagnosis, were collected and analyzed. The selected patients were divided into 2 groups: those with primary or secondary malignancies (PSM) and those with primary benign tumors (PB). Chi-squared tests were used to evaluate differences between the two groups. Logistic regression was performed to explore potential risk factors related to the differentiation of PSM and PB, and a receiver operating characteristic (ROC) curve was used to evaluate their diagnostic values.

Results: Ninety-one patients were selected; 54 were male, and the median age was 56 years old. Between the groups of PSM and PB, sex ($p=0.004$), age ($p=0.029$), tumor size ($p<0.001$), isolated lesion ($p<0.001$) and imaging diagnosis ($p<0.001$) were significantly different, while tumor size ($p=0.001$), sex ($p=0.047$) and imaging diagnosis ($p=0.002$) were independent predictors of PSM. With ROC curve analysis, risk factors $\geq 2$ was the optimal cutoff to differentiate these adrenal tumors, and their sensitivity and specificity were 73 and 77%, respectively. With a median follow-up of 32 months, only 4 of 32 patients with PB died from cancer, and 24 of 47 patients with PSM died from cancer, although aggressive treatment was performed.

Conclusions: Tumor size, sex and imaging diagnosis were independent predictors of adrenal primary or secondary malignancies. These predictors might be helpful for differentiation of adrenal tumors in patients with previous/synchronous extra-adrenal cancers.

Keywords: Adrenal tumor, Extra-adrenal cancer, Predictor, Differentiation
frequently deemed to be metastatic lesions [7]. However, if the mass is not a metastasis, the clinical decision is extremely different, so proper preoperative diagnostic studies are necessary. Additionally, the guidelines of adrenal incidentaloma in 2016 recommend evaluating an adrenal tumor as benign or malignant at initial management, and then sequential treatment is based on this decision [9]. Therefore, an incorrect diagnosis could result in inappropriate treatment of adrenal tumors: over treatment or overlooked. This study investigated the differentiation of adrenal malignant and benign tumors in patients with a history of extra-adrenal malignant tumors.

Methods
From April 1991 to November 2015, patients with adrenal tumors and a history of extra-adrenal malignancy were retrieved from Sun Yat-sen University Cancer Center and The First Affiliated Hospital of Sun Yat-sen University. In total, 183 patients with adrenal tumors had previous/synchronous extra-adrenal malignancies; then, those patients without pathological results were excluded, and ninety-one patients met our criteria. The clinical data, including sex, age, hormone evaluation, pathological diagnosis, interval time between diagnosis of the two tumors, tumor size and imaging characteristics, were retrospectively collected. From the pathological results, these adrenal tumors were categorized into 2 groups: primary or secondary malignancies (PSM) and primary benign tumors (PB). Based on radiological reports, tumors with a tumor density $> 10$ HU or enhancement of density $> 20$ HU on CT scan, a maximum standardized uptake value (SUVmax) $> 4.0$ on 18F-FDG PET/CT, nonuniform enhancement and irregular margins were considered as suspected adrenal malignancies.

For patients with isolated adrenal lesions, clinical and imaging characteristics were analyzed, and risk factors for predicting adrenal malignancy were investigated.

Based on IBM-SPSS Statistics™, version 20 (IBM-Corp., Armonk, NY), the Chi-square test was used to analyze the relationship between pathological diagnosis and clinical/radiological features. Univariate and multivariate logistic regression analyses were performed to explore risk factors for PSM, and a receiver operating characteristic (ROC) curve was used to evaluate their diagnostic values. All tests were two-tailed, and $p < 0.05$ was considered to be statistically significant.

Results
Fifty-two patients with PSM and 39 with PB were investigated in this study. The median age was 56 years old (9 to 80 years), and 54 patients were male. Tumor size ranged from 0.5 to 12.0 cm (median, 2.7 cm) (Table 1). In 3 patients with primary malignancy, 2 had adrenal cortical carcinoma and 1 had neuroendocrine carcinoma, with a size range from 6.1 cm to 12.0 cm. In 39 patients with PB, 24 had cortical adenoma, 10 had pheochromocytoma, 3 had nodular hyperplasia, 1 had ganglioneuroma and 1 had no tumor.

Hormonal evaluation was performed in 56 patients, 6 of whom were diagnosed with pheochromocytoma, 7 with hypercortisolism, 1 with subclinical Cushing syndrome, 1 with aldosteronism, 2 with adenocortical hyposecretion, and 39 with nonfunctional tumors.

The most common extra-adrenal cancers were lung carcinoma, followed by gastrointestinal (15 colorectal cancer and 2 gastric cancer), hepatic and urological cancers (Table 2). In the others group, esophageal cancer and ovarian cancer were 2, cervical cancer, nasopharyngeal carcinoma, neuroendocrine carcinoma, pancreatic carcinoma, submandibular neuroblastoma, testicular stroma and thymic carcinoma were 1. Adrenal metastasis was most common in patients with primary lung and liver cancer, and no metastasis was detected in patients with thyroid cancer.

According to comparative analysis, tumor size, sex and age were different between PSM and PB. The overall median interval time between extra-adrenal cancer and adrenal lesion was 15.5 months (0 to 146 months), and the median time interval of PSM was almost twice that of PB (18.5 vs 9 months), although this difference was not significant ($p = 0.620$). An ROC curve was performed to find the optimal cut-off value of tumor size, which was 3.2 cm. For tumor size $\geq 3.2$ cm or $< 3.2$ cm, the proportions of malignant tumors were 80 and 43%, respectively.

Most PB were isolated lesions, and extra-adrenal malignancies with isolated adrenal metastasis were associated with better survival when the adrenal lesion was dissected. So how to differentiate patients with adrenal PSM or not was of clinical significance to isolated adrenal lesions. The association of PSM and PB with the clinical and imaging characteristics was analyzed for those with solitary adrenal masses (Table 3). There were 38 patients with PB and 31 with PSM. With a median follow-up of 32 months, only 4 patients with PB died from cancer, including 1 breast cancer, 1 ovarian cancer, 1 kidney cancer and 1 bladder cancer. And 24 with PSM died from cancer, although aggressive treatment was performed, including 10 lung cancer, 5 colorectal cancer, 4 liver cancer, 3 urinary cancer, 1 breast cancer and 1 esophageal cancer.

Multivariate logistic regression analysis showed that tumor size, sex and imaging diagnosis were independently associated with PSM in patients with solitary adrenal tumors, regardless of age and location ($p = 0.074$ and 0.908, respectively) (Table 4). Consequently, we considered a better approach based on the number of risk
factors, which included tumor size, sex and imaging diagnosis. To compare the predictive value of the new approach with the single risk factor, we performed an ROC curve analysis (Fig. 1). The area under curve (AUC) of the new approach was 0.830, which was higher than the AUC of the other approaches (95% CI: 0.735–0.925; P < 0.001); the optimal cut-off value was 2 (sensitivity: 77.4%; specificity: 76.3%). Of the 33 cases with risk factors ≥2, 24 were PSM; when the cut-off was 1, the sensitivity and specificity were 100 and 26%, respectively.

**Discussions**

Adrenal glands are the fourth most common site of metastases in malignant diseases [10]. Abrams et al. found that 27% of cases involved the adrenal glands in 1000 consecutive autopsies of patients with carcinoma [11].

| Table 1 Clinical and imaging characteristics of patients with PSM and PB |
|---------------------------------|------------------|------------------|------------------|-----------|
| Clinical and imaging feature    | Total (%)        | PB (n = 39)      | PSM (n = 52)     | P value   |
| Age (years), median (range)     | 56(9–80)         | 52 (23–80)       | 58(9–75)         | 0.070     |
| ≤ 55                            | 44 (48.4)        | 24(54.5)         | 20(45.5)         | 0.029     |
| > 55                            | 47 (51.6)        | 15(31.9)         | 32(68.1)         |           |
| Gender                          |                  |                  |                  |           |
| Female                          | 38(41.8)         | 23 (60.5)        | 15 (39.5)        | 0.004     |
| Male                            | 53 (58.2)        | 16 (30.2)        | 37 (69.8)        |           |
| Location                        |                  |                  |                  |           |
| Right                           | 37(40.7)         | 20(54.1)         | 17(45.9)         | 0.201     |
| Left                            | 42(46.2)         | 15(35.7)         | 27(64.3)         |           |
| Bilateral                       | 12(13.2)         | 4(33.3)          | 8(66.7)          |           |
| Size (cm), median (range)       | 2.7(0.5–12.0)    | 2.3(0.9–5.7)     | 3.4(0.5–12.0)    | 0.001     |
| ≤3.2                            | 56(61.5)         | 32 (57.1)        | 24 (42.9)        | < 0.001   |
| ≥3.2                            | 35(38.5)         | 7 (20.0)         | 28 (80.0)        |           |
| Isolated lesion                 |                  |                  |                  |           |
| No                              | 22 (24.2)        | 1 (4.5)          | 21 (95.5)        | < 0.001   |
| Yes                             | 69 (75.8)        | 38 (55.1)        | 31 (44.9)        |           |
| Imaging diagnosis               |                  |                  |                  |           |
| Malignant                       | 61 (67.0)        | 17 (27.9)        | 44 (72.1)        | < 0.001   |
| Benign                          | 30 (33.0)        | 22 (37.3)        | 8 (26.7)         |           |
| Interval time (month), median (range) | 15.5 (10–146)  | 9(0–146)         | 18.5(0–91)       | 0.620     |

PSM primary or secondary malignancies found in patient with history of extra-adrenal malignancy
PB primary benign tumors found in patient with history of extra-adrenal malignancy

| Table 2 Clinical characters of patients stratified by extra-adrenal malignancy |
|---------------------------------|------------------|------------------|------------------|-----------|
| Cancer diagnosis                | No.              | Age (year), Mean (range) | Gender | Mass size (cm) | Mass size (cm) | Metastasis: Primary malignancy: PB | Surgical approaches |
|                                |                  |                  | Male: Female | Median (range) | ≤3.2: ≥3.2: |                      |                   |
| Lung cancer                     | 20               | 58(36–70)        | 14: 6       | 2.7(1.5–9.5) | 13: 7: 7    | 17 (0: 3) | 12: 7                  |
| Gastrointestinal cancer         | 17               | 59(43–75)        | 9: 8        | 2.3(0.5–6.5) | 14: 3: 7    | 7 (0: 10) | 7: 8                   |
| Liver cancer                    | 15               | 56(34–80)        | 11: 4       | 2.8(1.4–7.7) | 8: 7: 8     | 11 (1: 3) | 7: 7                   |
| Urinary cancer                  | 13               | 53(34–75)        | 9: 4        | 3.0(0.5–10.5) | 8: 5: 6     | 6 (0: 7) | 2: 10                  |
| Thyroid cancer                  | 9                | 36(23–51)        | 4: 5        | 2.8(0.9–5.7) | 5: 4: 5     | 0 (0: 9) | 6: 3                   |
| Breast cancer                   | 6                | 53(42–65)        | 0: 6        | 2.8(2.0–12.0) | 4: 2: 1     | 1 (1: 4) | 3: 2                   |
| The others                      | 11               | 48(0–66)         | 7: 4        | 4.2(1.0–8.1) | 4: 7: 4     | 7 (1: 3) | 4: 7                   |
| Total                           | 91               | 53(9–80)         | 54: 37      | 2.7(0.5–12.0) | 56: 35: 49 | 3: 39: 41 | 44*                   |

* Six patients underwent biopsy only
PB primary benign tumors found in patient with history of extra-adrenal malignancy
Table 3 Clinical and imaging characteristics of patients with solitary adrenal mass

| Clinical and imaging feature | Total (%) | PB (n = 38, 55.1%) | PSM (n = 31, 44.9%) | P value |
|-----------------------------|-----------|--------------------|---------------------|---------|
| Age (years)                 |           |                    |                     |         |
| ≤ 55                        | 35 (50.7) | 23 (65.7)          | 12 (34.3)           | 0.071   |
| > 55                        | 34 (49.3) | 15 (44.1)          | 19 (55.9)           |         |
| Gender                      |           |                    |                     | 0.019   |
| Male                        | 36 (52.2) | 15 (41.7)          | 21 (58.3)           |         |
| Female                      | 33 (47.8) | 23 (69.7)          | 10 (30.3)           |         |
| Size                        |           |                    |                     | < 0.001 |
| < 3.2 cm                    | 43 (62.3) | 31 (72.1)          | 12 (27.9)           |         |
| ≥ 3.2 cm                    | 26 (37.7) | 7 (26.9)           | 19 (73.1)           |         |
| Imaging diagnosis           |           |                    |                     | < 0.001 |
| Malignant                   | 42 (60.9) | 16 (38.1)          | 26 (61.9)           |         |
| Benign                      | 27 (39.1) | 22 (81.5)          | 5 (18.5)            |         |
| The number of risk factors  |           |                    |                     |         |
| < 1                         | 10 (14.5) | 10 (100)           | 0 (0.0)             | 0.002   |
| ≥ 1                         | 59 (85.5) | 28 (47.5)          | 31 (52.5)           |         |
| < 2                         | 36 (52.2) | 29 (80.6)          | 7 (19.4)            | < 0.001 |
| ≥ 2                         | 33 (47.8) | 9 (27.3)           | 24 (72.7)           |         |
| < 3                         | 57 (82.4) | 37 (64.9)          | 20 (35.1)           | < 0.001 |
| ≥ 3                         | 12 (17.6) | 1 (8.3)            | 11 (91.7)           |         |

PSM primary or secondary malignancies found in patient with history of extra-adrenal malignancy
PB primary benign tumors found in patient with history of extra-adrenal malignancy

Table 4 Univariate and multivariate logistics analyses of the clinical and imaging features for PSM in patients with solitary adrenal tumors

| Diagnostic parameter | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | P value             | Hazard(95% CI)        | P value   |
| Age                  | 0.074               | 3.552(1.015–12.429)   | 0.047     |
| Gender               | 0.021               | 9.835(2.521–38.363)   | 0.001     |
| Location             | 0.908               | 7.378(1.923–28.312)   | 0.004     |
| Size                 | < 0.001             | 1.000 (1.000–1.000)   | 1.000     |
| Imaging diagnosis    | 0.001               | 1.000 (1.000–1.000)   | 1.000     |

PSM primary or secondary malignancies found in patient with history of extra-adrenal malignancy
Furthermore, it was reported that approximately 50–75% of clinically imperceptible adrenal masses of cancer patients were metastases [7, 12–14]. The general assumption that an adrenal mass in a patient with concurrent or prior extra-adrenal cancer is a metastasis rather than a primary tumor may result in unnecessary and inappropriate cancer-directed management in clinical practice [7]. Therefore, in 2016, the guidelines for adrenal incidentaloma recommended that adrenal masses should be diagnosed as benign or malignant at the beginning of management of patients with extra-adrenal malignancy [9]. In addition, differentiation between PSM and PB is a critical problem in the clinical management of these adrenal tumors, especially for patients with isolated adrenal lesions, because adrenalectomy can offer increased survival outcomes when the lesion is isolated in the gland [15].

In our study, 57% of patients had PSM, which is in accordance with previous reports. Most of these patients had metastases, and only 3 had primary malignancies. There were still 39 patients with benign masses who were at potential risk of over-treatment, although some of the masses consisted of active hormones. Similar to the results of our previous report, most solitary adrenal lesions were benign tumors, and functional tumors were not rare, including pheochromocytoma [16]. In this study, more than 30% patients didn’t undergo hormonal evaluation, and pheochromocytoma and hypercortisolism presented about 25% in these patients with hormonal investigation, so misdiagnosis might lead to severe surgical complications. Thus, hormonal evaluation should be performed regularly as recommended by recent guidelines. For these patients with solitary adrenal tumors, diagnostic analysis demonstrated that sex, tumor size and imaging diagnosis were independent predictors of PSM. Compared to the index of any single risk factor, the comprehensive risk factor index (≥1 risk factors) had better diagnostic value for differentiating PSM from PB, and its sensitivity and specificity were 77 and 76%, respectively. Importantly, with a median follow-up of 32 months, over 50% of patients with PSM died of cancer, which was much higher than those with PB, although aggressive treatment was performed. For patients with solitary adrenal metastasis, resection could improve their oncological outcomes. Therefore, it is critical to differentiate malignant tumors from benign tumors for adrenal tumors with extra-adrenal cancers.

In clinical practice, the tumor size and imaging diagnosis play important roles in the differentiation between benign and malignant adrenal tumors. For adrenal tumors with extra-adrenal malignancy, these two factors are still helpful. In this study, the sensitivity of imaging diagnosis was about 85%, which was little lower than that of previous report. Most of adrenal malignancies (49/52) were metastasis in this study, and this status might affect the diagnostic value of imaging. What’s more, a threshold of 4 cm is often used as an indication of adrenalectomy, and our study showed that a threshold of 3.2 cm was proven to have the highest diagnostic value in this cohort. Compared to male patients, female patients were more likely to have benign adrenal tumors. Overall, these three independent factors were related to PSM in patients with previous/synchronous extra-adrenal malignancies. In fact, the cut-off of 2 risk factors had the best diagnostic efficacy, but the sensitivity was unsatisfactory, with a false-negative > 20%. It is possible that a cut-off of 1 risk factor with a sensitivity of 100% would be better in clinical practice.

Jeffrey T. Lenert et al. found that renal cell carcinoma was the most common origin of adrenal metastasis in patients with a history of extra-adrenal malignancy (30.8%) from 1971 to 2000 [7]. Lung cancers predominantly outnumbered renal cancers in our study, and the proportions of lung and renal cancer were 22 and 11%, respectively. Selection bias might have also played a role in this study, and patients with multi-organ metastasis, which is often determined by easy-access to organs other than the adrenal gland, were not included in this study.

In recent years, several studies have focused on the diagnosis of adrenal tumors. Our previous study revealed that malignant and functional tumors are not rare in patients with adrenal incidentaloma and that a history of other cancers is not associated with adrenal malignancy [16]. Byeon et al. and colleagues demonstrated that high pre-contrast HU, male sex, and metachronous adrenal mass were associated with malignant adrenal lesions, which was similar to the results of our study [17]. However, this finding is far from perfect, and fine needle aspiration could be a reliable examination method for selected patients, although there is a potential risk of hypertensive crisis [10]. Our study determined that a comprehensive analysis of these risk factors could improve the evaluation of adrenal tumors in patients with other cancers at initial management.

Because of the retrospective nature of this study, which represented more than 12 years of clinical experience, some patients didn’t have hormonal evaluation in this study, and imaging evaluations were not necessarily standardized, so we were not able to examine the explicit attenuation values. The small population and selection biases in these two medical centers were also limitations. However, these two affiliated institutes are the largest medical centers in South China, which may represent a good profile of adrenal tumors in patients with other cancers. Further research with prospective and multicenter studies would be useful to guide the understanding of patients with adrenal masses and a history of known extra-adrenal malignancies.
Conclusions
Tumor size > 3.2 cm, male sex and malignant imaging diagnosis were independent predictive factors for solitary PSM, and a new index with a number of these risk factors improved differential diagnosis. Further research with prospective studies would be useful to guide the management of patients with incidentally discovered adrenal masses and a history of extra-adrenal cancer.

Abbreviations
PB: primary benign tumors found in patient with history of extra-adrenal malignancy; PSM: primary or secondary malignancies found in patient with history of extra-adrenal malignancy; ROC curve: receiver operating characteristic curve

Acknowledgments
Not applicable.

Authors’ contributions
LT, YLY, KHX, HTL and XLL were responsible for data collection and analysis, interpretation of the results, and writing the manuscript. FFZ and ZKQ were responsible for conducting the study design, data analysis and interpretation. All authors have read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in the [Research Data Deposit public platform] repository, [http://www.researchdata.org.cn]. The approval RDD number is RDDA2019001107.

Ethics approval and consent to participate
Due to the retrospective nature of this study, ethics approval by Institutional Review Board of Sun Yat-sen University First Affiliated Hospital was obtained (No. 2016077) and the data were used confidentially for research work. Informed consent was written by every patient when they referred to hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, China. 2Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong, China.

Received: 28 December 2018 Accepted: 19 August 2019
Published online: 27 August 2019

References
1. Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol. 2002;56:95–101.
2. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental indeterminate adrenal mass on CT (> 10 HU) in patients without cancer: is further imaging necessary? Follow-up of 321 consecutive indeterminate adrenal masses. AJR Am J Roentgenol. 2002;179:1119–23.
3. Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and Ameri-can Association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. 2009;15(Suppl 1):1–20.
4. Pedziwiatr M, Major P, Piaserka M, et al. Laparoscopic transperitoneal adrenalectomy in morbidly obese patients is not associated with worse short-term outcomes. Int J Urol. 2017;24:59–63.
5. Pacak K, Eisenhofer G, Grossman A. The incidentally discovered adrenal mass. N Engl J Med. 2007;356:2005.
6. Chavez-Rodriguez J, Pasieka JL. Adrenal lesions assessed in the era of laparoscopic adrenalectomy: a modern day series. Am J Surg. 2005;189:581–5 discussion 5-6.
7. Lenert JT, Barretta CC Jr, Kudelka AP, et al. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery. 2001;130:1060–7.
8. Angelis A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997;47:279–85.
9. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175:G1–G34.
10. Cingam S, Karanchi H. Cancer, Metastasis, Adrenal. Treasure Island (FL): StatPearls; 2017.
11. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer. 1950;3:74–85.
12. Mansmann G, Lau J, Bøck E, Rothenberg M, Miyachi Y, Bornstein SR. The clinically inappropriate adrenal mass: update in diagnosis and management. Endocrinology. 2004;55:300–9.
13. Gillams A, Roberts CM, Shaw P, Spiro SG, Goldstraw P. The value of CT scanning and percutaneous fine needle aspiration of adrenal masses in biopsy-proven lung cancer. Clin Radiol. 1992;46:18–22.
14. Belldegrun A, Hussain S, Seltzer SE, Loughlin KR, Gittes RF, Richie JP. Incidentally discovered mass of the adrenal gland. Surg Gynecol Obstet. 1986;163:203–8.
15. Spartalis E, Drikos I, Ioannidis A, et al. Metastatic carcinomas of the adrenal glands: from diagnosis to treatment. Anticancer Res. 2019;39(6):2699–710.
16. Ye YL, Yuan XX, Chen MK, Dai YP, Qin ZK, Zheng FF. Management of adrenal incidentaloma: the role of adrenalectomy may be underestimated. BMC Surg. 2016;16:41.
17. Byeon KH, Ha YS, Choi SH, Kim BS, Kim HT, Yoo ES, Kwon TG, Lee JN, Kim TH. Predictive factors for adrenal metastasis in extra-adrenal malignancy patients with solitary adrenal mass. J Surg Oncol. 2018 Dec;118(8):1271–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions